Drugs / FCR001
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05098145 | Nov 2021 → Nov 2026 | diffuse cutaneous systemic sclerosis | Talaris Therapeutics Inc. | Withdrawn | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01649388 | Oct 2012 → Feb 2023 | — | Talaris Therapeutics Inc. | Withdrawn | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03995901 | Oct 2019 → Feb 2023 | transplant rejection | Talaris Therapeutics Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FCR001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03995901 ↗ |
| Modality | Cell therapy | “FCR001 is a novel, cryopreserved allogeneic somatic cell therapy” NCT01649388 ↗ |
| Route | Intravenous | “FCR001 is a cell therapy product that is administered by intravenous (IV) infusion” NCT05098145 ↗ |